Summit Therapeutics PLC ((SMMT)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Summit Therapeutics PLC is conducting a significant clinical study titled A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3). The study aims to evaluate the effectiveness of Ivonescimab combined with chemotherapy compared to Pembrolizumab with chemotherapy, focusing on overall survival and progression-free survival as primary endpoints.
The study tests two interventions: Ivonescimab, a biological agent, combined with chemotherapy, and Pembrolizumab, another biological agent, also combined with chemotherapy. Both are administered via IV injections and are intended to treat metastatic non-small cell lung cancer.
This Phase 3 study is interventional, with a randomized allocation and a parallel intervention model. It employs a quadruple masking approach, ensuring that participants, care providers, investigators, and outcomes assessors are blinded. The primary purpose of the study is treatment-focused.
The study began on June 1, 2023, with an estimated completion date set for October 1, 2025. The primary completion date is yet to be specified, but the last update was submitted on October 1, 2025, indicating ongoing progress.
For investors, this study could have significant implications for Summit Therapeutics’ stock performance. Positive results could enhance investor sentiment and position the company favorably against competitors in the oncology sector, particularly in the treatment of non-small cell lung cancer.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.